ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced that it has received a $5 million tranche from Hercules Technology Growth Capital, Inc. The $5 million was based upon ADMA achieving clinical endpoints of a Phase III clinical study of RI-002 as a treatment for Primary Immunodeficiency Disease (PIDD), under its existing loan and security agreement.

"We are very pleased to have achieved this key, positive Phase III milestone. We have enjoyed working with the Hercules team, and receiving this additional $5 million will further strengthen our current cash position. This funding will supplement and enhance our commercialization planning, plasma inventory build-up and will allow for the initiation of staffing for our commercial infrastructure," stated Adam Grossman, President & CEO.

ADMA is a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases.

Hercules Technology Growth Capital, Inc. is a leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science, and energy and renewable technology, at all stages of development. Since inception (December 2003), Hercules has committed more than $4.6 billion to over 300 companies and is a lender of choice for entrepreneurs and venture capital firms seeking growth capital financing.